Kevin Coppa
Overview
Explore the profile of Kevin Coppa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
5277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim E, Coppa K, Abrahams S, Hanchate A, Mohan S, Lesser M, et al.
PLoS One
. 2025 Jan;
20(1):e0316892.
PMID: 39752456
Transitional care management (TCM) visits have been shown to reduce 30-day readmissions, but it is unclear whether the decrease arises from the TCM visit itself or from clinic-level changes to...
2.
Ho M, Levy T, Koulas I, Founta K, Coppa K, Hirsch J, et al.
Int J Med Inform
. 2023 Nov;
181:105286.
PMID: 37956643
Background: COVID-19 is a challenging disease to characterize given its wide-ranging heterogeneous symptomatology. Several studies have attempted to extract clinical phenotypes but often relied on data from small patient cohorts,...
3.
Hirsch J, Jhaveri K, Abate M, Molmenti E, Coppa K, Nair V
Clin Nephrol
. 2023 Jun;
100(3):140-142.
PMID: 37366556
No abstract available.
4.
Coppa K, Kim E, Oppenheim M, Bock K, Zanos T, Hirsch J
J Gen Intern Med
. 2023 Feb;
38(10):2298-2307.
PMID: 36757667
Background: Non-arrivals to scheduled ambulatory visits are common and lead to a discontinuity of care, poor health outcomes, and increased subsequent healthcare utilization. Reducing non-arrivals is important given their association...
5.
Levy T, Coppa K, Cang J, Barnaby D, Paradis M, Cohen S, et al.
Nat Commun
. 2022 Nov;
13(1):6812.
PMID: 36357420
Clinical prognostic models can assist patient care decisions. However, their performance can drift over time and location, necessitating model monitoring and updating. Despite rapid and significant changes during the pandemic,...
6.
Jarrett M, Licht W, Bock K, Brown Z, Hirsch J, Coppa K, et al.
JMIRx Med
. 2021 Oct;
2(3):e29638.
PMID: 34606522
Background: Neutralizing monoclonal antibody (MAB) therapies may benefit patients with mild to moderate COVID-19 at high risk for progressing to severe COVID-19 or hospitalization. Studies documenting approaches to deliver MAB...
7.
Goldin M, Lin S, Kohn N, Qiu M, Cohen S, Barish M, et al.
J Thromb Thrombolysis
. 2021 Jun;
52(4):1032-1035.
PMID: 34146235
There is a need to discriminate which COVID-19 inpatients are at higher risk for venous thromboembolism (VTE) to inform prophylaxis strategies. The IMPROVE-DD VTE risk assessment model (RAM) has previously...
8.
Spyropoulos A, Cohen S, Gianos E, Kohn N, Giannis D, Chatterjee S, et al.
Res Pract Thromb Haemost
. 2021 Mar;
5(2):296-300.
PMID: 33733028
Background: Antithrombotic guidance statements for hospitalized patients with coronavirus disease 2019 (COVID-19) suggest a universal thromboprophylactic strategy with potential to escalate doses in high-risk patients. To date, no clear approach...
9.
Giannis D, Barish M, Goldin M, Cohen S, Kohn N, Gianos E, et al.
J Thromb Thrombolysis
. 2021 Mar;
51(4):897-901.
PMID: 33665766
Venous thromboembolism (VTE) has emerged as an important issue in patients with COVID-19. The purpose of this study is to identify the incidence of VTE and mortality in COVID-19 patients...
10.
Kim E, Coppa K, Hirsch J, Abrahams S, Johnson J, Lesser M, et al.
BMJ Open
. 2021 Feb;
11(2):e042965.
PMID: 33558355
Objective: To describe the pattern of hydroxychloroquine use and examine the association between hydroxychloroquine use and clinical outcomes arising from changes in the US Food and Drug Administration (FDA)'s recommendation...